Abstract
Each year 40,000 people are diagnosed with primary brain tumors. Malignant gliomas account for more than 50% of them and are universally fatal despite aggressive surgery and combined chemoradiotherapy. Identification of novel therapeutic targets has been challenging. New areas of interest are now focusing on exploiting special metabolic adaptations these tumors have developed in response to the stress caused by their rapid growth rate, exceeding their vascular supply. This article is an attempt to review a controversial strategy of modulating tumor biology by understanding their metabolic characteristics, how they differ from normal healthy cells, and implementing therapies that include nutritional interventions. Although fasting as part of the management of brain malignancies is controversial and may be contrary to popular opinion, developing supportive evidence in targeting their special metabolic profile is promising and fascinating.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
